Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Bayer
< Previous
1
2
3
4
5
6
7
Next >
Bayer to present new analyses adding to the depth of knowledge on the cardiovascular and renal outcomes of KERENDIA® (finerenone)
October 27, 2021
From
Bayer
Via
Business Wire
During Breast Cancer Awareness Month, Bayer Shines a Light on the Impact of Breast Density on Breast Cancer Risk
October 25, 2021
From
Bayer
Via
Business Wire
Bayer fuels leading market positions in Crop Science through delivery of unmatched innovation
October 19, 2021
From
Bayer
Via
Business Wire
Bayer Appoints New General Managers for Nutritionals and Digestive Health Businesses
October 05, 2021
From
Bayer
Via
Business Wire
Updated Vitrakvi® (larotrectinib) Sub-Analysis at ATA 2021 Supports Efficacy and Safety in Adult and Pediatric TRK Fusion Thyroid Cancer Patients
October 04, 2021
From
Bayer
Via
Business Wire
Bayer Issues Voluntary Recall of Specific Lotrimin® and Tinactin® Spray Products Due to the Presence of Benzene
October 01, 2021
From
Bayer
Via
Business Wire
Midol® by Bayer Receives Honorable Mention in Fast Company’s 2021 Innovation by Design Awards
September 28, 2021
From
Bayer
Via
Business Wire
Bayer Hires Nicole Hayes as Director of U.S. External Communications
September 28, 2021
From
Bayer
Via
Business Wire
On the 15th Anniversary of World Contraception Day Bayer Releases Survey Results that Highlight the Role of Contraceptives in Women’s Lives
September 27, 2021
From
Bayer
Via
Business Wire
Bayer Extends Clinical Development Program for KERENDIA® (finerenone) With Phase III Study to Investigate Use in Patients With Nondiabetic Chronic Kidney Disease
September 20, 2021
From
Bayer
Via
Business Wire
Latest Analyses of Vitrakvi® (larotrectinib) Support Consistently Meaningful Clinical Profile for Both Adult and Pediatric Patients with TRK Fusion Cancer
September 16, 2021
From
Bayer
Via
Business Wire
NUBEQA® (darolutamide) Impact on Local Symptoms Evaluated in Men with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
September 14, 2021
From
Bayer
Via
Business Wire
Andes Raises USD 15 Million in Series A Funding Co-Led by Leaps by Bayer and Cavallo Ventures
September 14, 2021
From
Bayer
Via
Business Wire
Tickers
OTC
Bayer Announces Recipients of the Second Annual Pulmonary Hypertension Accelerated Awards
September 10, 2021
From
Bayer
Via
Business Wire
Bayer to Highlight Expanded Research from Growing Oncology Portfolio at ESMO Congress 2021
September 09, 2021
From
Bayer
Via
Business Wire
Bayer and Luke Bryan Team Up Again for “Here’s to the Farmer” Campaign
September 08, 2021
From
Bayer
Via
Business Wire
Bayer Starts Phase III Clinical Development Program OASIS With Investigational Product, Elinzanetant
August 31, 2021
From
Bayer
Via
Business Wire
Bayer Announces KERENDIA® (finerenone) Reduces the Risk of Cardiovascular Outcomes in New Phase III FIGARO-DKD Study in Adults With Chronic Kidney Disease (Stages 1-4) Associated With Type 2 Diabetes
August 28, 2021
From
Bayer
Via
Business Wire
FDA Label Updates Reflect Bayer’s Commitment to Women’s Healthcare
August 25, 2021
From
Bayer
Via
Business Wire
Bayer Announces Filing of Petition to U.S. Supreme Court for Review of Hardeman Decision
August 16, 2021
From
Bayer
Via
Business Wire
Bayer Strengthens Drug Discovery Platform Through Acquisition of Vividion Therapeutics
August 05, 2021
From
Bayer
Via
Business Wire
Bayer Provides Update on Path to Closure of Roundup™ Litigation
July 29, 2021
From
Bayer
Via
Business Wire
Denise Vitola Joins Bayer Communications Team
July 26, 2021
From
Bayer
Via
Business Wire
Bayer Once Again Earns Top Marks in 2021 Disability Equality Index
July 15, 2021
From
Bayer
Via
Business Wire
Bayer’s KERENDIA® (finerenone) Receives U.S. FDA Approval for Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes
July 10, 2021
From
Bayer
Via
Business Wire
Bayer’s KERENDIA® (finerenone) Receives U.S. FDA Approval for Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes
July 09, 2021
From
Bayer
Via
Business Wire
Bayer Submits Regulatory Applications for Oncology Treatment Investigational Combination of Aliqopa® (copanlisib) and rituximab in the U.S. and EU
June 21, 2021
From
Bayer
Via
Business Wire
FDA Approves Astepro® Allergy Nasal Spray for Over-the-Counter Use in the United States
June 17, 2021
From
Bayer
Via
Business Wire
ZERO – The End of Prostate Cancer and Bayer Band Together with Twisted Sister’s Jay Jay French to Raise Awareness about Prostate Cancer Screening and Treatment
June 17, 2021
From
Bayer
Via
Business Wire
Bayer Announces First ‘Precision Oncology Patient Innovation Awards’
June 16, 2021
From
Bayer
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.